Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution
- PMID: 11698274
- DOI: 10.1182/blood.v98.10.2935
Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution
Abstract
In 1999 a working group of the World Health Organization (WHO) published a revised classification for myelodysplastic syndromes (MDS): RA, RARS, refractory cytopenia with multilineage dysplasia (RC+Dys), RAEB I and II, del (5q) syndrome, and MDS unclassifiable. Chronic myelomonocytic leukemia (CMML) and RAEB-t were excluded. Standard French-American-British (FAB) and new WHO classifications have been compared in a series of patients (n = 431) from a single center, analyzing morphologic, clinical, and cytogenetic data. According to the WHO findings, dysgranulocytopoiesis or dysmegakaryocytopoiesis only were found in 26% of patients with less than 5% medullary blasts. These patients are thus unclassified and should remain in the subgroups RA and RARS. Splitting of heterogeneous RAEB into 2 subgroups according to blast count was supported by a trend to a statistically significant difference in the single-center study population. Patients with CMML whose white blood cell counts are above 13 000/microL may be excluded from the MDS classification, as warranted by WHO, but a redistribution of patients with dysplastic CMML according to medullary blast count leads to more heterogeneity in other WHO subgroups. Although the natural courses of RAEB-T and acute myeloid leukemia (AML) with dysplasia are different, comparable median survival durations after treatment in patients with RAEB-T and AML were in favor of the proposed 20% medullary blast threshold for AML. The homogeneity of subgroups was studied by evaluating prognostic scores. A significant shift into lower IPSS risk groups was evident in the new classification. These data cannot provide evidence for the new WHO proposal, which should not be adopted for routine clinical use at present. Some of its aspects can provide a starting point for further studies involving refined cytogenetics and clinical results.
Comment in
-
Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary.Blood. 2002 Apr 15;99(8):3074-5. doi: 10.1182/blood.v99.8.3074. Blood. 2002. PMID: 11949634 No abstract available.
-
Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts.Blood. 2002 May 15;99(10):3870-1; author reply 3871. doi: 10.1182/blood-2001-11-0120. Blood. 2002. PMID: 12014369 No abstract available.
Similar articles
-
Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.Leukemia. 1996 Jan;10(1):20-6. Leukemia. 1996. PMID: 8558932
-
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.Leuk Res. 2000 Dec;24(12):983-92. doi: 10.1016/s0145-2126(00)00088-6. Leuk Res. 2000. PMID: 11077111
-
[Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].Pathologe. 2000 Jan;21(1):1-15. doi: 10.1007/s002920050001. Pathologe. 2000. PMID: 10663664 Review. German.
-
Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.Ann Hematol. 2006 Aug;85(8):502-13. doi: 10.1007/s00277-005-0030-z. Epub 2006 May 20. Ann Hematol. 2006. PMID: 16715299
-
Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.Leukemia. 1997 Feb;11(2):206-11. doi: 10.1038/sj.leu.2400558. Leukemia. 1997. PMID: 9009082 Review.
Cited by
-
Apoptotic rate in patients with myelodisplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines.J Cell Mol Med. 2003 Jul-Sep;7(3):313-21. doi: 10.1111/j.1582-4934.2003.tb00232.x. J Cell Mol Med. 2003. PMID: 14594556 Free PMC article.
-
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.J Natl Compr Canc Netw. 2011 Jan;9(1):30-56. doi: 10.6004/jnccn.2011.0005. J Natl Compr Canc Netw. 2011. PMID: 21233243 Free PMC article.
-
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.Cancer Res. 2009 Nov 1;69(21):8482-90. doi: 10.1158/0008-5472.CAN-09-1153. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826047 Free PMC article.
-
Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).Wien Klin Wochenschr. 2003 Aug 14;115(13-14):515-36. doi: 10.1007/BF03041035. Wien Klin Wochenschr. 2003. PMID: 13677270 Review.
-
Models of granulocyte DNA structure are highly predictive of myelodysplastic syndrome.Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5008-11. doi: 10.1073/pnas.0400838101. Epub 2004 Mar 29. Proc Natl Acad Sci U S A. 2004. PMID: 15051892 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous